A Single Centre, Randomised, Double-blind, Placebo-controlled, Fed-fasted, Single and Multiple Ascending Dose Trial of XEN-D0103 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs XEN D0103 (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Sponsors Xention
- 20 Mar 2012 Results reported in a Xenion media release.
- 20 Mar 2012 Status changed from recruiting to completed, according to a Xenion media release.
- 12 Sep 2011 New trial record